Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder

N/A

Waitlist Available

Led By Z. Jeffrey Daskalakis, MD, PhD.

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline in hrsd-24 / y-bocs / bprs at date of symptom remission or date of the 24th treatment, whichever comes first, assessed up to 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD). However, its use is limited by significant adverse effects on memory and cognition. In addition, ECT cannot be precisely targeted, since it relies on unpredictable pathways of electrical conduction through the brain. Magnetic seizure therapy (MST) is currently under investigation as a targetable, cognition-sparing alternative to ECT. MST uses magnetic fields rather than electrical stimuli for seizure induction, dramatically reducing the passage of induced current through undesired brain regions. 10 years of experimental studies have established the safety of MST in animal and human subjects. This pilot study will investigate whether MST has similar efficacy to ECT, with fewer cognitive side effects, in patients with severe depression, schizophrenia, and OCD.

Eligible Conditions

Depression
Schizophrenia
Obsessive-Compulsive Disorder
Schizoaffective Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline in hrsd-24 / y-bocs / bprs at date of symptom remission or date of the 24th treatment, whichever comes first, assessed up to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline in hrsd-24 / y-bocs / bprs at date of symptom remission or date of the 24th treatment, whichever comes first, assessed up to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline in hrsd-24 / y-bocs / bprs at date of symptom remission or date of the 24th treatment, whichever comes first, assessed up to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Score on rating scale that corresponds to diagnosis: i) Hamilton Rating Scale for Depression, 24-item (HRSD-24); or ii) Yale-Brown Obsessive Compulsive Scale (Y-BOCS); or iii) Brief Psychiatric Rating Scale (BPRS)

Secondary study objectives

Cognitive Functioning

Neuroimaging (brain structure and activity)